Clinical Trials Logo

Moderate Alzheimer's Disease clinical trials

View clinical trials related to Moderate Alzheimer's Disease.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT03959553 Withdrawn - Clinical trials for Moderate Alzheimer's Disease

GV1001 Subcutaneous(SC) for the Treatment of Moderate Alzheimer's Disease (AD)

Start date: September 1, 2019
Phase: Phase 2
Study type: Interventional

The current study is being conducted by the Sponsor to evaluate the efficacy and safety of GV1001 (0.56 mg and 1.12 mg) administered subcutaneously as a treatment for moderate Alzheimer's disease (AD). GV1001 has been shown to inhibit neurotoxicity, apoptosis, and the production of reactive oxygen species induced by amyloid beta in neural stem cells by mimicking the extra-telomeric functions of human telomerase reverse transcriptase (hTERT). In nonclinical studies, using both mild (early stage) and severe (late stage) AD mouse models, GV1001 has been shown to improve cognitive function and memory, as well as significantly reduce the amount of amyloid beta and tau proteins. The multifunctional effect of GV1001 makes it a promising therapeutic option for the treatment for AD.